CellsBin Closes Series A Led by 108 BioCapital

CellsBin closed a Series A financing led by 108 BioCapital to move its rare-cell analysis platform from promising technical evidence toward commercial adoption, broader partnerships, and stronger clinical evidence. The Branford, Connecticut company announced the closing on September 22, 2026, but did not disclose the amount or valuation.

The investment centers on a hard measurement problem in cell therapy. Therapeutic cells can remain biologically meaningful after they become too scarce for conventional tools to characterize reliably. CellsBin is developing instruments and assays that aim to detect those cells while preserving information about what each cell is doing.

What CellsBin announced

The September 22 closing announcement names 108 BioCapital as the Series A lead. CellsBin said it will use the proceeds to accelerate commercial adoption, expand strategic and channel partnerships, advance product development, strengthen its clinical evidence base, and grow commercial, scientific, and technical teams.

The public disclosure leaves major financial details open. CellsBin did not disclose the round size, valuation, security, ownership terms, or participating investors beyond the lead. An earlier AdvanceCT report said CellsBin had secured Series A funding for production scale, a broader clinical footprint, commercialization, and six planned jobs across Branford and New Haven. The September release is the verified closing announcement.

CEO Ali Kabiri, PhD, and CTO Nima Sarshar, PhD, lead the company. CellsBin describes itself as a tech-bio business focused on rare-cell analysis for precision medicine. Its thesis is that a useful rare-cell platform should combine sensitivity with phenotype rather than force researchers to choose between finding a cell and understanding its state.

The measurement gap in cell therapy

Cell and gene therapies do not stop interacting with a patient at infusion. Engineered cells can persist, expand, contract, and change state over time. Researchers may want to know whether those cells remain present, whether they retain a functional phenotype, and how those measurements relate to durability, response, or safety.

That becomes difficult when the target population falls below the practical detection range of routine tools. Spectral flow cytometry provides rich phenotypic information, but confidence declines as the target becomes rarer. Molecular methods can reach lower concentrations, but a genetic signal does not show the phenotype of an individual living cell.

CellsBin's Scout product is designed for therapeutic-cell monitoring. The company reports sensitivity near one cell per million, support for more than 30 surface and intracellular markers, approximately 2 mL of blood input, and a 48-hour reporting target. Those are product specifications from CellsBin and should not be read as independent clinical-performance claims.

Scout sits on the broader Polaris platform, which integrates photonics, microfluidics, artificial intelligence, analytics, assays, and cloud infrastructure. CellsBin also describes Insight, a research-use-only blood assay under development for multiple-myeloma burden and risk stratification.

Early evidence supports the technical thesis

CellsBin has started to present evidence that its approach can detect rare therapeutic cells beyond the range of spectral flow cytometry. The evidence is encouraging, but it remains early.

In a blinded spiked-sample study presented at ASCO 2026, CB-Scout reported a limit of detection of approximately 0.61 cells per million. The comparator spectral flow-cytometry workflow reported a limit near 30 cells per million. The study also reported no false positives across more than 21 million blank peripheral-blood mononuclear cells.

That study addresses analytical sensitivity under a controlled design. It does not establish that the measurement improves patient outcomes or clinical decisions.

A separate retrospective ASCO 2026 study examined samples from five Yale Cancer Center patients. CellsBin reported detection of rare CAR-T cells at later time points when spectral flow cytometry no longer detected them. The small cohort makes this a signal for further study, not a validation of broad clinical utility.

Earlier work presented at ASH 2024 described preliminary transformer-based rare-cell detection. CellsBin also holds an active U.S. patent covering devices for biological analysis, with Kabiri named as inventor.

Together, these sources support the platform's technical rationale. They do not yet verify repeatability across many programs, regulatory clearance, customer adoption, commercial scale, or a link between the measurements and better treatment decisions.

What the Series A needs to prove

The financing and 108 BioCapital partnership give CellsBin more room to turn an instrument and early assay evidence into a dependable operating system for longitudinal cell measurement. That transition requires more than better sensitivity.

First, the company needs repeatable performance across sample types, cell-therapy constructs, sites, and operators. A rare-cell result is useful only if researchers can trust that it means the same thing across time and settings.

Second, CellsBin must connect measurements to decisions. Biopharma teams need to know which readouts change trial design, patient monitoring, manufacturing strategy, or development risk. More data is not automatically more useful data.

Third, the company has to make the workflow operationally practical. Production capacity, turnaround time, quality systems, clinical partnerships, and integration into existing programs will determine whether the platform can move beyond specialist studies.

The Series A announcement makes that operating agenda visible through planned commercial, scientific, and technical hiring. The financing is not proof that CellsBin has completed the commercial transition. It is capital for the work required to attempt it.

Why this round matters

The investment case for CellsBin rests on a simple idea: the most consequential cell may also be the hardest one to see. If therapeutic cells remain active after conventional instruments lose confidence, researchers need a way to recover both the signal and the cell's phenotype.

CellsBin has shown early evidence that it can push the analytical boundary. The next test is whether that sensitivity can become a repeatable, decision-relevant workflow across real development programs.

That is the real Series A milestone. The company is financing the move from an impressive rare-cell measurement to an infrastructure layer that cell-therapy teams can use when the easy signal is gone.